Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis

Journal of Dermatological Treatment

Volumn 26, Issue 4, 2015, Pages 326-328

  Mazur, Małgorzata ^a   Karczewski, Jacek ^a   Lodyga, Martha ^a   Zaba, Ryszard ^a   Adamski, Zygmunt ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Apremilast psoriasis vulgaris; inhibitors of phosphodiesterase; psoriasis arthritis

Indexed keywords

ADALIMUMAB; APREMILAST; ETANERCEPT; INFLIXIMAB; PHOSPHODIESTERASE IV INHIBITOR; USTEKINUMAB; INTERLEUKIN DERIVATIVE; PHOSPHODIESTERASE IV; TUMOR NECROSIS FACTOR;

ARTICLE; CANADA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EUROPE; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; TREATMENT INDICATION; UNITED STATES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; DRUG EFFECTS; IMMUNOLOGY; PSORIASIS;

ARTHRITIS, PSORIATIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; INTERLEUKINS; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939206606     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.991267     Document Type: Article

References (21)

1. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83: 1583-90.
2. Claveau D, Chen SL, O'Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004;310:752-60.
3. Eigler A, Siegmund B, Emmerich U, et al. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63:101-7.
4. Serezani CH, Ballinger MN, Aronoff DM, et al. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39:127-32.
5. Uyemura K, Yamamura M, Fivenson DF, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993; 101:701-5.
6. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419-29.
7. Schafer PH, Day RM. Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4. J Am Acad Dermatol. 2013;68:1041-2.
8. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther. 2013;7:201-10.
9. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016-29.
10. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842-55.
11. Papp KA, Kaufmann R, Thaci D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27:e376-83.
12. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738-46.
13. Strand V, Fiorentino D, Hu C, et al. Improvements in patientreported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes. 2013;11:82.
14. Reich K, Papp K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 1) [oral presentation]. Annual meeting of the American Academy of Dermatology, Miami, 2013.
15. Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor in nail and scalp psoriasis: 52-week results from the ESTEEM 1 study [abstract P1601]. Annual Congress of the European Academy of Dermatology and Venereology, Istanbul; 2013.
16. Shutty B, West C, Pellerin M, Feldman S. Apremilast as a treatment for psoriasis. Expert Opin Pharmacother. 2012;13:1761-70.
17. Strand V, Schett G, Hu C, Stevens RM. Patient-reported healthrelated quality of life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol. 2013;40:1158-65.
18. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156-67.
19. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial [abstract L13]. Arthritis Rheum. 2012;64:4172-3.
20. Celgene International Sarl. Apremilast achieves statistical significance for the primary endpoint of the first phase III study (PALACE-1) in patients with psoriatic arthritis [press release]; 2012. Available from http://ir.celgene.com/phoenix.zhtml?c111960 &pirol-newsArticle&ID1714113&highlight. Accessed August 6, 2013.
21. Poole RM, Ballantyne AD. Apremilast: first global approval. Drugs. 2014;74:825-37.